Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTMX NASDAQ:EDIT NASDAQ:PTCT NASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTMXCytomX Therapeutics$3.82$3.56$1.72▼$8.21$650.11M2.085.78 million shs5.12 million shsEDITEditas Medicine$3.65$2.90$1.66▼$4.54$357.36M2.12.63 million shs4.20 million shsPTCTPTC Therapeutics$83.31$73.63$43.17▼$87.50$6.91B0.532.65 million shs6.75 million shsSRPTSarepta Therapeutics$19.28$17.85$10.41▼$25.32$2.04B0.213.77 million shs4.36 million shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTMXCytomX Therapeutics0.00%+12.85%+18.63%-16.23%+54.03%EDITEditas Medicine0.00%+28.07%+31.29%+36.70%+42.58%PTCTPTC Therapeutics0.00%-1.33%+21.30%+22.93%+69.50%SRPTSarepta Therapeutics0.00%+14.42%+18.72%-17.00%+5.99%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTMXCytomX Therapeutics$3.82$3.56$1.72▼$8.21$650.11M2.085.78 million shs5.12 million shsEDITEditas Medicine$3.65$2.90$1.66▼$4.54$357.36M2.12.63 million shs4.20 million shsPTCTPTC Therapeutics$83.31$73.63$43.17▼$87.50$6.91B0.532.65 million shs6.75 million shsSRPTSarepta Therapeutics$19.28$17.85$10.41▼$25.32$2.04B0.213.77 million shs4.36 million shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTMXCytomX Therapeutics0.00%+12.85%+18.63%-16.23%+54.03%EDITEditas Medicine0.00%+28.07%+31.29%+36.70%+42.58%PTCTPTC Therapeutics0.00%-1.33%+21.30%+22.93%+69.50%SRPTSarepta Therapeutics0.00%+14.42%+18.72%-17.00%+5.99%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTMXCytomX Therapeutics 2.91Moderate Buy$12.10216.75% UpsideEDITEditas Medicine 2.57Moderate Buy$5.4047.95% UpsidePTCTPTC Therapeutics 2.71Moderate Buy$91.369.66% UpsideSRPTSarepta Therapeutics 2.08Hold$24.8128.68% UpsideCurrent Analyst Ratings BreakdownLatest SRPT, CTMX, EDIT, and PTCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/29/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)6/16/2026CTMXCytomX Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)6/11/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)6/9/2026PTCTPTC Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$75.00 ➝ $108.005/27/2026EDITEditas Medicine TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/27/2026PTCTPTC Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$76.00 ➝ $85.005/26/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/19/2026CTMXCytomX Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$6.005/19/2026CTMXCytomX Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$6.005/11/2026PTCTPTC Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)5/11/2026CTMXCytomX Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$17.00 ➝ $11.00(Data available from 7/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTMXCytomX Therapeutics$76.20M8.53N/AN/A$0.58 per share6.59EDITEditas Medicine$40.52M8.82N/AN/A$0.28 per share13.04PTCTPTC Therapeutics$1.73B3.99$8.78 per share9.49($2.56) per share-32.54SRPTSarepta Therapeutics$2.18B0.93N/AN/A$10.89 per share1.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTMXCytomX Therapeutics-$17.37M-$0.41N/AN/AN/A-166.40%-36.61%-28.02%8/6/2026 (Estimated)EDITEditas Medicine-$160.06M-$1.23N/AN/AN/A-281.59%-677.39%-58.25%8/11/2026 (Estimated)PTCTPTC Therapeutics$682.64M-$2.33N/A39.483.83-22.58%-362.45%-6.76%8/6/2026 (Estimated)SRPTSarepta Therapeutics-$713.41M-$0.96N/A9.310.20-2.94%7.56%2.94%8/5/2026 (Estimated)Latest SRPT, CTMX, EDIT, and PTCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026CTMXCytomX Therapeutics-$0.14-$0.10+$0.04-$0.10$4.68 million$10.26 million5/7/2026Q1 2026PTCTPTC Therapeutics-$0.45-$0.03+$0.42-$0.03$217.42 million$272.55 million5/6/2026Q1 2026SRPTSarepta Therapeutics$0.9760$3.16+$2.1840$2.88$474.16 million$730.80 million5/5/2026Q1 2026EDITEditas Medicine-$0.30-$0.26+$0.04-$0.26$6.37 million$2.83 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTMXCytomX TherapeuticsN/AN/AN/AN/AN/AEDITEditas MedicineN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTMXCytomX TherapeuticsN/A10.3810.38EDITEditas MedicineN/A3.223.22PTCTPTC TherapeuticsN/A2.442.36SRPTSarepta Therapeutics0.564.632.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTMXCytomX Therapeutics67.77%EDITEditas Medicine71.90%PTCTPTC TherapeuticsN/ASRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipCTMXCytomX Therapeutics3.80%EDITEditas Medicine3.10%PTCTPTC Therapeutics5.50%SRPTSarepta Therapeutics6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTMXCytomX Therapeutics170170.19 million163.72 millionOptionableEDITEditas Medicine23097.91 million94.87 millionOptionablePTCTPTC Therapeutics1,41082.95 million78.39 millionOptionableSRPTSarepta Therapeutics1,372105.58 million98.29 millionOptionableSRPT, CTMX, EDIT, and PTCT HeadlinesRecent News About These CompaniesSarepta Therapeutics (NASDAQ:SRPT) Raised to "Buy" at Wall Street ZenJuly 4 at 1:36 AM | americanbankingnews.comSRPT Stock Climbs After Sarepta Seeks Permanent FDA Nod For Two Duchenne TherapiesJune 30, 2026 | stocktwits.comSSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 30, 2026 | finance.yahoo.comSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 30, 2026 | businesswire.comSarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy DrugsJune 30, 2026 | benzinga.comSarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®June 30, 2026 | finance.yahoo.comSarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®June 30, 2026 | businesswire.comSRPT or PRTA: Which Is the Better Value Stock Right Now?June 24, 2026 | zacks.comSarepta's Elevidys Showing Signs of Stabilization as siRNA Pipeline Gains Importance, RBC SaysJune 18, 2026 | finance.yahoo.comSarepta: Caution Still Warranted Despite FDA's Gene Therapy-Friendly StanceJune 18, 2026 | seekingalpha.comING Groep NV Cuts Stock Holdings in Sarepta Therapeutics, Inc. $SRPTJune 10, 2026 | marketbeat.comAll You Need to Know About Sarepta Therapeutics (SRPT) Rating Upgrade to BuyJune 8, 2026 | finance.yahoo.comIs Sarepta (SRPT) Using New Equity Plans To Quietly Redefine Its Post‑Profitability Playbook?June 8, 2026 | finance.yahoo.comSarepta Therapeutics, Inc. (SRPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comSRPT vs. ARGX: Which Stock Is the Better Value Option?June 8, 2026 | finance.yahoo.comAll You Need to Know About Sarepta Therapeutics (SRPT) Rating Upgrade to BuyJune 8, 2026 | zacks.comSRPT vs. ARGX: Which Stock Is the Better Value Option?June 8, 2026 | zacks.comBioGene Therapeutics Inc. Appoints Ty Howton to Board of DirectorsJune 8, 2026 | finance.yahoo.comSarepta Therapeutics, Inc. $SRPT Shares Sold by BNP Paribas Financial MarketsJune 7, 2026 | marketbeat.comImproving Profitability Supports Sarepta Therapeutics Inc. (SRPT) as One of the Most Shorted Small-Cap Stocks to BuyJune 5, 2026 | finance.yahoo.comImproving Profitability Supports Sarepta Therapeutics Inc. (SRPT) as One of the Most Shorted Small-Cap Stocks to BuyJune 5, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesTesla’s EV Rebound Leaves Rivian and Lucid Facing a Tougher Investor TestBy Jessica Mitacek | June 6, 2026Uncle Sam Plugs In: Nuclear Energy’s Cash Flow Moment Is Finally HereBy Jeffrey Neal Johnson | June 26, 2026Synchrony’s Comeback Is Hiding in Plain SightBy Peter Frank | June 10, 20263 ETFs For the Coming Genomics RevolutionBy Nathan Reiff | June 7, 2026Bread’s Comeback Is Real—But Is the Easy Money Gone?By Peter Frank | June 17, 2026SRPT, CTMX, EDIT, and PTCT Company DescriptionsCytomX Therapeutics NASDAQ:CTMX$3.82 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$3.82 +0.01 (+0.13%) As of 07/2/2026 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Editas Medicine NASDAQ:EDIT$3.65 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$3.58 -0.07 (-1.97%) As of 07/2/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.PTC Therapeutics NASDAQ:PTCT$83.31 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$83.28 -0.03 (-0.03%) As of 07/2/2026 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Sarepta Therapeutics NASDAQ:SRPT$19.28 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$19.30 +0.02 (+0.08%) As of 07/2/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Shorting the Grid: Bloom Energy’s $25B AI Power Play Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
